Telisotuzumab

• CAT Number: I042205
• CAS Number: 1781223-80-0
• Purity: ≥95%

Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity[1].
Telisotuzumab (ABT-700) (10 μg/mL, 24 h) inhibits the proliferation of SNU5 cells and leads to an increase in pro-apoptotic Bim and a decrease in anti-apoptotic Bcl-xL, thereby inducing apoptosis[1].
Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) effectively antagonizes constitutively activated c-Met and downstream signaling, thereby inhibiting tumor growth in SCID mice with Hs746T cells[1].

Reference

[1]. Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105.
 [Content Brief]